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Abstract
T-cell biology has regained importance in the pathogenesis of
rheumatoid arthritis. Despite the significant improvements
associated with the introduction of tumor necrosis factor-α block-
ade, reasonable proportions of failures and suboptimal responses
have been reported, necessitating a search for alternative targeted
therapies. This has included drug therapy designed to interrupt
T-cell activation via the co-stimulation pathway. Abatacept is a
recombinant fusion protein that blocks the co-stimulatory signal
mediated by the CD28-CD80/86 pathway, which is required for
T-cell activation. Several clinical trials have confirmed the safety
and efficacy of this drug in the treatment of rheumatoid arthritis.
This review summarizes the clinical data supporting this line of
treatment and considers the safety and efficacy data from phase II
and III trials.
Introduction
The role of T cells in rheumatoid arthritis (RA) pathogenesis
has regained central importance in recent years. Several
observations over the years support a fundamental role for
T cells in RA: the association of RA susceptibility with HLA-
DR allele on major histocompatibility complex (MHC) class II
[1,2]; the induction of an inflammatory arthritis by transfer of
CD4+ T cells from affected animals into healthy syngeneic
recipients [3,4]; and the induction of clinical features of RA in
human synovium-severe combined immunodeficient mice [5].
In addition, RA synovium contains a rich infiltrate of activated
CD4+ cells and MHC class II [6], with correlation seen between
synovial T-cell numbers and severity of joint damage [7].
During the 1990s, the widely accepted concept of cytokine
networks perpetuating disease, with tumor necrosis factor
(TNF)-α assuming a hierarchical role [8], was supported by
the success of TNF-α blocking treatments [9,10]. The lack of
universal benefit from TNF-α blocking therapies [11], how-
ever, has focused attention on alternative immunological
mediators, including T cells.
The relative lack of success of T-cell-directed therapies
stimulated research into alternative methods of targeting
T-cell biology, including T-cell co-stimulation; of the multiple
co-stimulatory pathways that can upregulate or downregulate
T-cell activation, one of the best characterized is that
between CD28 and CD80/CD86 (B7 molecules). Both
CD80 and CD86 bind to cytotoxic T-lymphocyte antigen
(CTLA)4-immunoglobulin (Ig) complex (CD152), which
shares 30% homology with CD28 but has a 10 to 20 times
greater binding affinity to the B7 molecules [12]. CTLA4
expression and binding therefore competitively inhibit T-cell
activation in both naïve and primed CD4+ and CD8+ T cells,
disrupting CD28-dependent T-cell responses [13]. Advances
in drug development and protein engineering have facilitated
creation of targeted therapies, in this case to interrupt the
T-cell-activation pathway. The role of T cells in RA and, in
particular, the biology of co-stimulation is the subject of more
detailed discussion in other articles included in this
supplement. This review concentrates on the outcomes of
CTLA4-directed therapies in RA.
Co-stimulation signal blockade
Abatacept (CTLA4-Ig) is a soluble fusion protein that
consists of the extracellular domain of human CTLA4 linked
to the modified Fc (hinge, CH2 and CH3 regions) portion of
human IgG1. Like native CTLA4, the fusion protein binds
more avidly to CD80/86 than to CD28. Belatacept (LEA29Y)
is a second-generation CTLA4-Ig, which is currently in phase
III trials in transplantation.
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Therapeutic inhibition with CTLA4-Ig
A CTLA4-Ig fusion protein was initially applied in rodent
models of transplantation [14], in which graft survival was
prolonged. Subsequent application in nonhuman primate
organ transplantation studies, however, was unsuccessful. In
contrast, slowing of disease progression was observed in
several experimental animal models of autoimmune disease,
including lupus and glomerulonephritis [15,16]. CTLA4-Ig
prevented development of collagen-induced arthritis if it was
administered at the time of immunization, and it ameliorated
arthritis if it was given after the onset of disease [17].
Abatacept was therefore developed for application in auto-
immune disease, with a number of clinical studies conducted
to evaluate its use in RA (the focus of this supplement). To
address the poor outcomes in transplantation studies, further
development of CTLA4-Ig concentrated on improving its
binding to CD86 in particular (owing to its importance in
initiation of the immune reaction in primates), in order to
confer the more potent immunosuppressive action needed.
This led to the development of belatacept, a second-
generation CTLA4-Ig that exhibits superior binding to CD80
and CD86 as compared with the parent CTLA4-Ig.
Abatacept in initial clinical studies
The cumulative biological and experimental data provided the
basis for targeting CD28-mediated T-cell activation in human
disease with abatacept. The first clinical study to evaluate the
efficacy of abatacept was conducted in patients with
psoriasis; 46% of patients exhibited greater than 50%
sustained improvement in disease activity [18].
Abatacept in rheumatoid arthritis
Abatacept was subsequently applied in patients with RA. A
summary of the clinical efficacy data from each of the main
phase II and III trials of abatacept in RA is first presented,
followed by cumulative quality of life and safety data.
Phase II studies
Abatacept monotherapy in patients with rheumatoid arthritis
and a history of DMARD failure
An initial dose-ranging study provided preliminary clinical data
and has been the only study to assess safety and efficacy of
abatacept monotherapy in patients with active RA who had
previously failed disease-modifying antirheumatic drug
(DMARD) therapy [19]. In this double-blind, placebo-controlled
study, patients with RA received abatacept at 0.5 mg/kg,
2 mg/kg or 10 mg/kg doses, or placebo. Infusions were
administered at baseline and weeks 2, 4, and 8, with the primary
end-point being American College of Rheumatology (ACR)
response at 12 weeks. Ninety per cent of the patients were also
concurrently receiving prednisolone (≤10 mg/day). High
baseline disease activity, as indicated by high mean tender joint
and swollen joint counts (30.3 and 21.9, respectively), was
observed. Dose-dependent response to abatacept was seen;
44% of the 2 mg/kg group and 53% of the 10 mg/kg group
achieved the primary outcome of ACR20 (at least 20%
improvement in the ACR criteria for RA) response at 12 weeks,
as compared with 31% in the placebo group.
Abatacept plus methotrexate combination in patients with
rheumatoid arthritis and a history of DMARD failure
Two key studies provided the initial evidence base for
abatacept in combination with methotrexate in patients who
have failed DMARD treatment (the second providing 12-
month data following on from the first study).
The first phase IIb study compared abatacept in combination
with methotrexate versus methotrexate alone in patients with
active RA despite at least 6 months of methotrexate treatment
(10 to 30 mg/week) [20,21]. All patients exhibited erosive
change at baseline with high disease activity, and 90% of
patients were positive for rheumatoid factor. Despite these
poor prognostic features and long disease duration (mean
8.9 to 9.7 years for the three treatment groups), it is interest-
ing that only relatively mild functional impairment was
recorded (modified Stanford Health Assessment Question-
naire score 1.0 in all treatment groups). A total of 339
patients were randomly assigned to treatment for 6 months
with either 2 mg/kg (n = 105) or 10 mg/kg (n = 115) of
abatacept, or placebo (n = 119); a total of 259 patients (99,
82 and 78 patients in the 10 mg/kg, 2 mg/kg, and placebo
groups, respectively) completed the study. All patients con-
tinued background methotrexate therapy at a mean dose of
approximately 15 mg/week. Significantly greater ACR20
responses were seen in the 10 mg/kg group than in the
placebo group (60% versus 35.3%) but not with the 2 mg/kg
group (hence only 10 mg/kg was used in future studies).
ACR50 and ACR70 responses were also significantly greater
in both abatacept dose groups (Table 1).
In the long-term extension of this phase IIb study [21] the
investigators presented 12-month findings from patients who
continued blinded therapy for an additional 6 months, but in
this continuation study modification to methotrexate dose
with/without change in DMARD was permitted. A total of 90
patients in the 10 mg/kg abatacept group, 74 in the 2 mg/kg
abatacept group, and 71 in the placebo group completed
1 year of therapy. Similar response rates were observed at
12 months as compared with 6 months, suggesting
sustainability of response (Table 1). ACR50 and ACR70
response rates were also greater in the 10 mg/kg abatacept
group than in the placebo group (Table 1). Although rapidity
of response with abatacept is slower in comparison with
infliximab, high ACR response rates were observed from as
early as 30 days, with statistical significance from 90 days.
Improvement in response over time has also been suggested
to be a feature of abatacept therapy; in this study remission
rates (defined as Disease Activity Score using 28 joint counts
[DAS28] <2.6) progressively increased over the year in the
10 mg/kg abatacept group (34.8% at 12 months versus
10.1% in the placebo group; P < 0.001; Table 1). Low
disease activity scores (LDAS; DAS28 <3.2) were similar,Page 3 of 10
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being significantly greater in the 10 mg/kg abatacept group
than in the placebo group. Of the original 115 patients who
were treated with abatacept 10 mg/kg and methotrexate, 75
continued treatment (open label after the blinded portion of
study) for a total of 2 years. High ACR50 response rates
were maintained (54.7%), with an impressive 53% achieving
DAS28 criteria for remission.
It is worth noting that the ability to change DMARDs after
6 months might have influenced the perceived efficacy of
abatacept (although patients included had at least failed
methotrexate); also, despite long duration of disease, the
baseline functional impairment was lower compared with most
cohorts, which may lend itself toward greater responsiveness
to therapy. Finally, of the original 339 patients randomly
assigned to treatment, 235 patients completed the 12-month
study (only n = 90 in the 10 mg/kg abatacept group).
Abatacept plus etanercept in patients with rheumatoid arthritis
and a history of etanercept failure
Combination biologic therapy raises safety concerns,
particularly with regard to infection risk. In a 1 year multicentre,
randomized, double-blind controlled study [31], an evaluation
of the safety and efficacy of abatacept (2 mg/kg) in
combination with etanercept versus placebo and etanercept
was undertaken in patients who had failed etanercept (after at
least 3 months therapy). No treatment adjustments (including
corticosteroids) were allowed until a LTE phase (when those
who had received placebo plus etanercept were switched to
10 mg/kg abatacept). In all, 80/121 patients completed the
study (58 in the abatacept plus etanercept arm, and 22 in the
placebo plus etanercept arm), with all entering the LTE.
Essentially, no significant and meaningful difference in clinical
response was observed between these two treatment arms.
Safety issues were reported, however (discussed below).
Phase III studies
Several phase III studies have been undertaken including: the
AIM (Abatacept in Inadequate responders to Methotrexate)
study evaluated abatacept plus methotrexate in patients
failing DMARD treatment; the ATTEST (Abatacept or
infliximab versus placebo, a Trial for Tolerability, Efficacy and
Safety in Treating RA) study was a comparator study
between abatacept and infliximab; the ATTAIN (Abatacept
Trial in Treatment of Anti-TNF INadequate responders) study
evaluated abatacept plus methotrexate in patients failing TNF-
α blockade; and the safety study ASSURE (Abatacept Study
of Safety in Use with other Rheumatoid arthritis thErapies).
The findings of these studies are discussed below.
Abatacept plus methotrexate in patients with rheumatoid
arthritis and a history of DMARD failure (AIM study)
The AIM study sought to evaluate further the safety and efficacy
of 1 year of treatment with abatacept (using the 10 mg/kg dose
only) and methotrexate (n= 433) as compared with placebo
(n= 219) and methotrexate in patients with active RA who had
Available online http://arthritis-research.com/supplements/10/S1/S5
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.failed methotrexate treatment (at a dose ≥15 mg/week for at
least 3 months) [22]. After 6 months, alteration in methotrexate
dose, addition of another DMARD, or change in corticosteroid
dose (≤10 mg/day) was permitted. Formal assessment of
radiographic outcome was also included in this study (the only
clinical trial of abatacept to have radiographic data). Response
rates, and radiographic and functional outcomes were all
primary end-points. Eighty-nine per cent (n= 385) in the
abatacept and methotrexate group versus 74% (n= 162) in the
placebo group completed the study.
Similar improvements were detected at 6 months, with
continued improvement to 1 year. At 1 year, impressive
ACR20 response rates were noted in the abatacept group as
compared with the placebo group (73.1% versus 39.7%,
respectively). ACR50 and ACR70 responses were also
higher in the abatacept group than in the placebo group
(Table 1). DAS28 remission was observed in 23.8% in the
abatacept group as compared with 1.9% in the placebo
group at 1 year. The data further suggested that 1-year high
response rates (ACR70) were achieved early in study
duration; 49% achieved ACR70 for 6 consecutive months
and 21% for 9 consecutive months. The significant increase
in ACR20 response in the abatacept-treated group com-
pared with the placebo group was detected as early as day
15 (P = 0.008); this was mainly driven by patients’ and
physicians’ assessment of disease activity. Specific reference
to measures of biological improvement (C-reactive protein
[CRP] reduction) was made; this is in contrast to infliximab
and methotrexate studies, in which immediate CRP
suppression has been reported [9]. Two-year data from this
cohort were also recently reported [23], which demonstrate
sustained ACR responses and DAS28 reductions.
Specifically, ACR20, 50 and 70 responses of 80.3%, 55.6%
and 34.3% respectively were seen; 56.1% and 30.9% of
patients in the original abatacept group achieved DAS28
LDAS and DAS28 remission at 2 years.
Radiographic data were available for 92% of the patients
randomized in the study. Different scoring systems exist,
including the modified Sharp/van der Heijde score [24] and
the Genant-modified Sharp scoring system [25,26]. The latter
was employed in this study; it comprises scores at several
sites for erosion and joint space narrowing, to give a maximum
total Genant-modified Sharp score of 290. The data suggest
that over the 1-year period, those patients who received
abatacept plus methotrexate progressed at approximately half
the rate of patients who were on background placebo plus
methotrexate (1.07 units versus 2.4 units, respectively).
Although erosion scores also appeared to favor the abatacept
treated group, comparable median changes in joint space
narrowing and total scores were noted between the groups.
Two-year radiographic data are also now available, which
provide information on sustainability (from 467 of the original
652 patients [72%] randomized who continued on open-label
long-term extension [LTE] with abatacept therapy) [27]. For
those patients who had been on placebo and were switched
to abatacept, the rate of progression was considerably
diminished (from 2.4 units at 1 year to only 3.1 at the end of
the second year). Similarly, for those patients who completed
2 years on abatacept, impressive retardation in radiographic
progression was seen in the second year (essentially half the
progression seen in the first year, with 1.07 units in year 1 to
a total of 1.5 units in the second year). These data imply
reduction in structural damage over time, with the suggestion
that improvements in the second year appear to be better
even than those in the first year. Comparable data on radio-
graphic progression in abatacept-treated nonresponders (as
seen in infliximab-treated patients) were not directly reported.
The recent report also confirmed further inhibition of radio-
graphic progression during year 2 [23].
Abatacept or infliximab plus methotrexate in patients with
rheumatoid arthritis and a history of DMARD failure (ATTEST
study)
The more recent ‘ATTEST’ study (Abatacept or infliximab
versus placebo, a Trial for Tolerability, Efficacy and Safety in
Treating RA) was a comparator trial that compared abatacept
(n = 156), infliximab (n = 165), and placebo (n = 110; plus
background methotrexate) in a 1-year efficacy and safety trial
conducted in 431 patients with RA who had previously failed
methotrexate (≥15 mg/week) [28]. The study design was not
powered to distinguish between the effects of abatacept and
those of infliximab. After day 197, adjustments in DMARD
(including methotrexate dose with/without addition of other
DMARDs), corticosteroid (≤10 mg/day), or nonsteroidal anti-
inflammatory drug use was permitted. After 6 months,
placebo-treated patients could switch to abatacept. At 6
months, DAS28 improvements, European League against
Rheumatism (EULAR) responses, and ACR response rates
were all significantly better in the abatacept and infliximab
groups than in the placebo group (Table 1). Interestingly,
there were suggestions of greater ACR and EULAR
responses, and greater LDAS and DAS28 (erythrocyte sedi-
mentation rate) remission rates in the abatacept group than in
the infliximab group, and a more durable response in the
abatacept group, although it should be noted that in the
infliximab group only the 3 mg/kg dose was used (with no
opportunity to dose escalate). Nevertheless, the efficacy of
abatacept and infliximab relative to placebo appeared
comparable, with both being reasonable options within the
context of DMARD failure. (Safety profiles are discussed
below.)
Abatacept plus methotrexate in patients with rheumatoid
arthritis and a history of TNF-α blockade failure (ATTAIN study)
Application of alternatively targeted therapies within the
context of TNF-α blockade failure in RA formed the basis for
the ATTAIN study [29], which was a multicentre, randomized,
placebo-controlled study comparing abatacept (approxi-
mating 10 mg/kg) with placebo. Patients included had
Arthritis Research & Therapy    Vol 10 Suppl 1 Buch et al.
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month ACR20 response and Health Assessment Question-
naire (HAQ) disability index improvement of at least 0.3
formed the two primary end-points. Totals of 258 and 133
patients were randomly assigned to receive abatacept and
placebo, respectively, in addition to background DMARD
therapy. More than 70% of patients were seropositive and
more than 75% of patients in each group were receiving
background methotrexate. The majority of patients had failed
infliximab treatment (>60% in each group), with the rest
being essentially etanercept failures (>30%), because use of
adalimumab was not as widespread at the time of enrolment.
A total of 223/258 and 99/133 patients randomly assigned
to receive abatacept and placebo, respectively, completed
the study. At 6 months, significantly greater ACR20, ACR50,
and ACR70 response rates were seen in the abatacept-
treated group (ACR20 response rate 50.4%) as compared
with the placebo group (19.5%; Table 1). A higher proportion
of abatacept-treated patients achieved DAS28 LDA as well
as DAS28 remission at 6 months compared with placebo
(P < 0.001; Table 1); achieving such endpoints is impressive
in this particularly resistant cohort.
Subsequent to the 6-month double-blind study, an 18-month
open-label, LTE treatment with abatacept was reported [30],
which allowed sustainability of response (over 24 months) to be
examined. It confirmed durability of response in this refractory
group of patients. In patients originally randomly assigned to
abatacept, ACR responses (ACR20, ACR50, and ACR70)
were all maintained, with 6-month and 2-year ACR20
responses of 59.4% and 56.2%, respectively. These data
illustrate that abatacept is an attractive option in the
challenging group of patients who are resistant to TNF-α
blockade.
Function and quality of life
Function and quality of life assessment is a key component of
overall evaluation of therapeutic success; the aim of clinically
effective interventions is to reduce the burden of disease on
quality of life and impact on health outcomes. The trials
evaluating abatacept described above have all included
quality of life measures. The quality of life benefit has been a
particularly impressive feature of abatacept therapy.
Function
Improvement in modified HAQ (reported in the phase II trial
[21] as well as in the AIM study [22]) has been detected as
early as 30 days [21]. Two-year and 3-year patient data have
also confirmed sustained response in modified HAQ (49.3%
at 3 years), with significant improvement in physical function
also observed [32]. Functional improvement is difficult to
achieve in the challenging TNF-α-refractory group by virtue of
probable secondary damage that would be incurred; the
ATTAIN study is notable for the statistically greater benefits in
physical function (defined by improvement in HAQ-Disability
Index of at least 0.3) seen (by day 15) in the abatacept-
treated group, which was sustained at 2 years [29,30].
Quality of life (36-item Short Form)
Studies of abatacept have all generally confirmed improve-
ments in quality of life measures (including all domains and
summary scores of the 36-item Short Form), with sustained
physical and mental component scores in the LTE arm
[20,21]. The AIM study [22] also demonstrated significant
improvements in the same outcomes in the abatacept group,
which were maintained at 1 year. A recent report included a
comprehensive assessment of health-related quality of life
domains and confirmed positive effects [32].
Figures 1 and 2 and Table 2 detail the quality of life and
functional outcomes reported from the AIM and ATTAIN
studies respectively [32] and [33].
Safety
Abatacept with nonbiologic/biologic DMARDs and
co-morbidities
The ASSURE study was a 1-year, multicentre, double-blind,
placebo-controlled trial with safety as its end-point [34]. A
total of 1,441 patients with a wide range of co-morbidities,
including diabetes mellitus (7%), asthma (6%), chronic
obstructive pulmonary disease (4%), and congestive heart
failure (1%), were recruited and randomly assigned to either
receive abatacept or placebo, both in combination with oral
DMARDs, anti-TNF-α, or anti-IL-1 biologic agents. The safety
data for abatacept in combination with nonbiologic DMARDs
were comparable to those from other trials. Patients with
chronic obstructive pulmonary disease experienced more
frequent exacerbations on abatacept. Abatacept in combina-
tion with biologic agents, however, did not appear to be safe,
with increased incidence of serious infection and neoplasm;
hence, this combination is not recommended [34]. The
combination abatacept-etanercept study described above
[31] confirmed this poor safety profile. Table 3 summarizes
data from the ASSURE study.
The various trials discussed above confirmed the reassuring
safety profile of abatacept, with nasopharyngitis, headache,
and nausea being the most frequently reported adverse
events. The initial phase II/LTE study actually reported fewer
serious adverse events and a lower discontinuation rate in the
10 mg/kg abatacept group than in the 2 mg/kg abatacept
and placebo groups. In the AIM study [22], adverse events
led to more discontinuations in the abatacept group than in
the placebo group (4.2% versus 1.8%). Although the
incidence of serious adverse events was greater in the
abatacept group (mainly hospitalization due to disease flare
or elective surgery), the rate of discontinuation because of
serious adverse events was similar in both abatacept and
placebo groups. Increased incidence of infection, with more
cases of pneumonia, was noted in the abatacept group. Two
deaths (one in each treatment arm) were observed (aspergillo-
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P. aeruginosa infection in the second). In the ATTAIN study
[29] similar rates of discontinuation because of adverse
events and serious adverse events, and similar incidences of
serious infections were noted in the abatacept-treated and
placebo groups; these findings were corroborated by LTE
rates. The ATTEST trial study design allowed for comparison
between the two active treatments (abatacept and infliximab)
at 1 year. A higher rate of acute infusional reactions was seen
in the infliximab group versus abatacept group, 24.8 versus
7.1%, respectively [28]. Serious infections were fewer in the
abatacept group (1.3%) than in the placebo (2.7%) and
infliximab (4.2%) groups.
Malignancy
The initial phase III/LTE study [21] included one case of
bladder cancer, two cases of basal cell carcinoma and one
neoplasm in the 10 mg/kg abatacept group, and one case
each of endometrial cancer, squamous cell carcinoma and
malignant melanoma in the placebo group. Comparable inci-
dences of malignancy in both treatment groups in the AIM
study [22] were observed and included a large B-cell
lymphoma of thyroid (on a background of Hashimoto’s thyroid)
in the abatacept group as well as a case of endometrial
cancer in the placebo group. The ATTAIN [29] study identified
11 neoplasms during the 2-year period; five out of 11 were
nonmelanomatous skin cancers as well as a T-cell lymphoma.
Autoimmune disorders
Biologic agents have been associated with development of
alternative autoimmune disorders (for example, there is a
suggestion of lupus syndromes in patients treated with TNF-α
blockade [35] and psoriasis in those undergoing treatment
with rituximab [36]). Reports of new disease have been
reported in abatacept-treated patients, although no specific
association has been found. In the ATTAIN study [30], 15
cases of autoimmune disorders were reported; these inclu-
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Figure 1
Mean SF-36 (a) physical (PCS) and (b) mental (MCS) component
summary score by treatment group and visit (*P < 0.05; †P < 0.01; 
‡P < 0.001). Treatment groups are ‘Abatacept’ = abatacept + MTX and
‘Placebo’ = placebo + MTX. Reproduced from Ann Rheum Dis 2007,
66:189-194 [32] with permission from the BMJ Publishing Group.
Figure 2
Mean (a) Fatigue VAS score and (b) HAQ-DI score by treatment
group and visit (*P < 0.05; †P < 0.01; ‡P < 0.001). Treatment groups
are ‘Abatacept’ = abatacept + MTX and ‘Placebo’ = placebo + MTX.
Reproduced from Ann Rheum Dis 2007, 66:189-194 [32] with
permission from the BMJ Publishing Group.ded three cases of psoriasis and two patients with vasculitis.
Four of the cases were observed in the double-blind period
and 11 cases during 18 months of open-label treatment.
Infusion reactions
Abatacept infusions are administered relatively rapidly (over
30 minutes), with generally reassuring tolerability. A lower
incidence of acute infusion reactions was observed in the
abatacept group as compared with the placebo and infliixmab
groups in the ATTEST study [28] (5.1%, 10.0% and 18.2%,
respectively). The AIM study [22] reported more acute and
peri-infusional infusion reactions with abatacept than with
placebo, with two patients discontinuing because of severe
acute infusion reactions. One patient experienced hypersen-
sitivity (rash and chest pain) after the second infusion; the
second patient experienced severe hypotension during the
fourth infusion. Mild-to-moderate acute infusion reactions
were slightly more common in the abatacept-treated group
(5%) than in the placebo group (3%) in the ATTAIN study,
although no severe reactions were observed.
Immunogenicity
Immunogenicity studies, conducted as part of the previously
discussed trials, did not demonstrate significant production of
anti-abatacept antibodies, which is in keeping with the
properties and advantages of a fully humanized fusion
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Table 2
Quality of life outcomes from the ATTAIN trial [33]
Abatacept Placebo  P value 
(mean change  (mean change  (abatacept versus
from baseline) from baseline) placebo)
Physical functioning 5.3 1.2 0.0001
Physical role 6.7 0.8 <0.0001
Pain 8.7 2.2 <0.0001
General health 3.9 0.7 0.0002
Vitality 6.9 1.2 <0.0001
Social functioning 7.4 2.2 <0.0001
Emotional role 6.3 2.0 0.0133
Mental health 4.6 1.1 0.0012
Physical component score 6.5 1.0 <0.0001
Mental component score 5.5 1.7 0.0025
Fatigue VAS -22.1 -5.3 <0.0001
Quality of life components are shown from the ATTAIN study, which compared abatacept plus methotrexate versus placebo plus methotrexate in
patients with rheumatoid arthritis who were refractory to tumor necrosis factor-α inhibition. ATTAIN, Abatacept Trial in Treatment of Anti-TNF
Inadequate Responders; MOS, medical outcome study; VAS, visual analog score.
Table 3
Summary safety data from ASSURE [34]
Abatacept plus  Placebo plus  Abatacept plus  Placebo plus 
nonbiologic nonbiologic  biologic  biologic 
DMARD DMARD DMARD DMARD 
Number of events (%) (n = 856) (n = 418) (n = 103) (n = 64)
Death 5 (0.6) 4 (1.0) 0 0
Total adverse events 768 (89.7) 360 (86.1) 98 (95.1) 57 (89.1)
Serious adverse events 100 (11.7) 51 (12.2) 23 (22.3) 8 (12.5)
Discontinuations because of adverse events 43 (5.0) 18 (4.3) 9 (8.7) 2 (3.1)
Serious infection  22 (2.6) 7 (1.7) 6 (5.8) 1 (1.6)
Neoplasm (benign/malignant) 27 (3.2) 16 (3.8) 7 (6.8) 1 (1.6)
Number (%) of events are included for abatacept and placebo in combination with either nonbiologic DMARD or biologic DMARD at 1 year.
ASSURE, Abatacept Study of Safety in Use with other Rheumatoid arthritis thErapies; DMARD, disease-modifying antirheumatic drug.protein. Specifically, the monotherapy study [19] did not
identify antibodies to abatacept. In the combination with LTE
study [21], most patients had pre-existing antibodies against
CTLA4. Two patients produced antibodies against the
CTLA4-T portion (not the whole molecule), which were
transient in one and there was no follow up in the second. Six
patients (1.4%) in the AIM study exhibited antibody reactivity
to abatacept. The pattern of ACR20 responses in these
patients with anti-CTLA4 antibodies was unchanged, with no
evidence of a hypersensitivity reaction. In the larger, phase III
trial [29] antibodies against abatacept developed in 1.3% of
patients and were of low reactivity. More recent reporting of
immunogenicity in the phase II and III trials using direct form
enzyme-linked immunosorbent assay (more sensitive for the
phase III study) [37] confirmed these findings, with a mini-
mum of sequelae. Significant seroconversion for anti-nuclear
antibodies has not been noted; in the ATTAIN study [29] anti-
nuclear antibodies were detected in 7.5% of patients in the
abatacept group and 11.3% in the placebo group.
A recent report [38] summarized the safety findings by way of
an integrated safety analysis of five randomized, placebo-
controlled, double-blind, core abatacept clinical trials,
generating 4,764 patient-years of exposure in total.
Continued follow up will establish whether the current
acceptable safety profile is maintained with long-term
abatacept use.
Mechanism of action studies
In vitro and in vivo studies have demonstrated inhibition of
immune responses by CTLA4-Ig molecules, with down-
regulation of T-cell proliferation and inhibition of humoral
immune response [39]. Inhibition of the proliferation of both
circulating naïve and memory T cells has been observed [40],
which may assist in reducing the number of activated auto-
reactive T cells available for entry into the synovium. Other
studies have shown reduction in proinflammatory cytokine
production by antigen-presenting cells when synovial cells
were co-cultured with CTLA4-Ig [41]. Evaluation of
biomarkers in patients recruited as part of the AIM and
ATTAIN studies confirmed an effective cellular action [42];
specifically, reductions in rheumatoid factor, CRP, soluble
IL-2 receptor, IL-6, TNF-α, E-selectin, soluble intercellular
adhesion molecule-1, and matrix metalloproteinase III were
observed. T-cell proliferation studies demonstrated marked
inhibition when stimulated by dendritic cells, although this
effect was less pronounced with B cells as the antigen-
presenting cell [43].
A first mechanistic study employed dynamic contrast-enhanced
magnetic resonance imaging in combination with synovial
histology and gene expression techniques to determine the
effect of abatacept on the synovium of patients with RA
failing TNF-α blockade [44]. A modest (nonsignificant) reduc-
tion in synovial infiltrate was observed within the context of a
generalized reduction in proinflammatory gene expression,
particularly interferon-γ; these findings were complemented
by reduced synovial volume, as indicated by magnetic
resonance imaging. These data are in contrast to the
dramatic de-populating effect on the synovium observed with
TNF-α blocking agents [45,46], and suggest a greater
deactivating effect on the synovium (consistent with an
immunomodulatory effect of T-cell co-stimulation therapy).
Conclusion
The introduction of abatacept, the first T-cell co-stimulation
blocking therapy, has added to the growing armamentarium of
targeted therapies for the management of RA. It is clear that
abatacept is a safe and efficacious option for RA treatment,
including in the challenging group of patients who are
refractory to TNF-α blockade. It remains to be seen where
exactly abatacept will fit in with the rest of the biologic and
emerging therapies; emerging therapies; currently in the UK
and Europe, failure to respond to TNF-α blockade remains the
main application. The impressive and similar response rates in
TNF-α blockade failures to those observed in only DMARD
failure (included in the phase IIb trial) implies that the pathways
that are targeted with the two treatments remain distinct
(contrasting with observations seen using IL-1-directed therapy
in patients failing TNF-α blockade, which suggested that TNF-
α blockade failure predicts IL-1 blockade failure) [47].
Future applications of T-cell co-stimulation blockade are likely
to include its evaluation early in disease; the possibility of
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Key messages
￿ Lack of success of T-cell-directed therapies has
stimulated research into targeting T-cell co-
stimulation.
￿ CTLA4-Ig competitively inhibits T-cell activation
through its greater binding affinity to the B7
molecules.
￿ Abatacept is a soluble fusion protein that comprises
the extracellular domain of human CTLA4 linked to
the modified Fc portion of human IgG1.
￿ Clinical trials have demonstrated abatacept to be
efficacious in patients with RA who have failed
previous DMARDs with radiographic benefit shown
in MTX refractory study population.
￿ Trials have also shown abatacept to be an effective
option in patients who are refractory to TNF-α
inhibition with impressive quality of life
improvements.
￿ Future strategies are likely to evaluate abatacept in
early disease.Available online http://arthritis-research.com/supplements/10/S1/S5
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achieving drug-free remission with such an agent is an
exciting prospect. Use of abatacept in other autoimmune
diseases is also under investigation, including in active lupus
nephritis, with increasing evidence arguing for a clinical trial
[48]. The suboptimal results observed in transplantation, in
particular, have led to the development of belatacept. The
latter is a second-generation CTLA4-Ig that exhibits superior
binding to CD80 and CD86 compared with CTLA4-Ig,
thereby having more potent immunosuppressive properties,
as are required for transplantation [49].
To conclude, abatacept represents the first clinical applica-
tion of co-stimulation blockade in RA. Its proven success in
RA will encourage its use in other disease groups and will
allow refinement of approaches to targeting the T-cell
pathway in specific microenvironments.
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